FIGURE 1



A
mAb binding to huCD100-his
OD
[mAb]
D2517/PBS
2503
C
mAb binding to cynoCD100-his
B
mAb binding to marmCD100-his
D
mAb binding to mouseCD100

Figure 2A



VX18 human CD100
Receptor Blocking Assay
% Blocking of humanCD100
to 293PLXNB1 cells
100
80
60
40
20
0
0
2
4
6
nM mAb
VX15 RS 12024
VX18 D2517

Figure 2B



VX18 cyno CD100
Receptor Blocking
% Blocking of cynoCD100 to 293PLXNB1 cells
100
80
60
40
20
0
0
2
4
6
nM mAb
VX15 RS 12024
VX18 D2517

Figure 2C



VX18 mouse
CD100 Receptor Blocking
% Blocking of mouseCD100 to 293PLXNB1 cells
100
80
60
40
20
0
0
2
4
6
nM mAb
VX15 RS 12024
VX18 D2517

Figure 2D



VX18 RatCD100
Receptor Blocking Assay
% Blocking of ratCD100 to 293PLXNB1 cells
100
80
60
40
20
0
0
2
4
6
nM mAb
VX15 RS 12024
VX18 D2517

Figure 3A



Tubo.A5
Mean Tumor volume, mm3
1000
800
600
400
200
0
0
20
40
60
80
Days post graft
Control Ig
αSEMA4D/ D2585
*

Figure 3B




Survival Tubo.A5
Percent survival
100
80
60
40
20
0
0
20
40
60
80
Time to Endpoint (days)
**
Control Ig
αSEMA4D/ D2585

Figure 3C



CR = complete tumor regression

**p<0.01, Fishers Exact test